146 related articles for article (PubMed ID: 26279289)
1. T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen.
Hartling HJ; Birch C; Gaardbo JC; Hove M; Trøseid M; Clausen MR; Gerstoft J; Ullum H; Nielsen SD
APMIS; 2015 Oct; 123(10):903-11. PubMed ID: 26279289
[TBL] [Abstract][Full Text] [Related]
2. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
Lee S; Hammond T; Watson MW; Flexman JP; Cheng W; Fernandez S; Price P
Clin Exp Immunol; 2010 Jul; 161(1):118-26. PubMed ID: 20408862
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
[TBL] [Abstract][Full Text] [Related]
5. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.
Caetano J; Martinho A; Paiva A; Pais B; Valente C; Luxo C
J Virol; 2008 Aug; 82(15):7567-77. PubMed ID: 18480446
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of chronic hepatitis viral C: new associations].
Ouzan D
Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659
[TBL] [Abstract][Full Text] [Related]
7. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
[TBL] [Abstract][Full Text] [Related]
8. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
[TBL] [Abstract][Full Text] [Related]
9. Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success.
Méndez-Lagares G; Lu D; Chen C; Terrault N; Segal MR; Khalili M; Monto A; Shen H; Manos MM; Lanier LL; Ryan JC; McCune JM; Hartigan-O'Connor DJ
J Immunol; 2018 Feb; 200(3):1124-1132. PubMed ID: 29263212
[TBL] [Abstract][Full Text] [Related]
10. T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.
Neau D; Galpérine T; Legrand E; Pitard V; Neau-Cransac M; Moreau JF; Ragnaud JM; Dupon M; Fleury H; Lafon ME
HIV Med; 2003 Apr; 4(2):120-6. PubMed ID: 12702132
[TBL] [Abstract][Full Text] [Related]
11. HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-α2b/ribavirin correlates with infection resolution.
Larrubia JR; Lokhande MU; Moreno-Cubero E; García-Garzón S; Miquel J; Parra-Cid T; González-Praetorious A; Perna C; Lázaro A; Sanz-de-Villalobos E
Cell Immunol; 2013; 286(1-2):31-8. PubMed ID: 24287274
[TBL] [Abstract][Full Text] [Related]
12. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
Coppola N; Pisaturo M; Sagnelli C; Sagnelli E; Angelillo IF
PLoS One; 2014; 9(4):e94542. PubMed ID: 24728219
[TBL] [Abstract][Full Text] [Related]
13. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.
Sreenarasimhaiah J; Jaramillo A; Crippin J; Lisker-Melman M; Chapman WC; Mohanakumar T
Hum Immunol; 2003 May; 64(5):497-504. PubMed ID: 12691700
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lawitz E; Gane E; Pearlman B; Tam E; Ghesquiere W; Guyader D; Alric L; Bronowicki JP; Lester L; Sievert W; Ghalib R; Balart L; Sund F; Lagging M; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1075-86. PubMed ID: 25467591
[TBL] [Abstract][Full Text] [Related]
15. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Buti M; Gordon SC; Zuckerman E; Lawitz E; Calleja JL; Hofer H; Gilbert C; Palcza J; Howe AY; DiNubile MJ; Robertson MN; Wahl J; Barr E; Forns X
Clin Infect Dis; 2016 Jan; 62(1):32-6. PubMed ID: 26371152
[TBL] [Abstract][Full Text] [Related]
16. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
de Lédinghen V; Laforest C; Hézode C; Pol S; Renault A; Alric L; Larrey D; Métivier S; Tran A; Jézéquel C; Samuel D; Zoulim F; Tual C; Pailhé A; Gibowski S; Bourlière M; Bellissant E; Pawlotsky JM
Clin Infect Dis; 2018 Mar; 66(7):1013-1018. PubMed ID: 29077864
[TBL] [Abstract][Full Text] [Related]
17. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
Alsaran K; Sabry A; Shaheen N
Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
[TBL] [Abstract][Full Text] [Related]
19. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; de Mendoza C; Cascajero A; Muñoz F; González-Lahoz J; Benito JM
Antivir Ther; 2007; 12(4):459-68. PubMed ID: 17668554
[TBL] [Abstract][Full Text] [Related]
20. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
Marchetti G; Nasta P; Bai F; Gatti F; Bellistrì GM; Tincati C; Borghi F; Carosi G; Puoti M; Monforte Ad
PLoS One; 2012; 7(2):e32028. PubMed ID: 22363790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]